| Title |
Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, March 2008
|
| DOI | 10.2147/ndt.s1826 |
| Pubmed ID | |
| Authors |
Jeffrey R Bishop, Mani N Pavuluri |
| Abstract |
Risperidone is a commonly used medication for the treatment of bipolar disorder and schizophrenia in children and adolescents. It has been studied as a monotherapy treatment in early onset schizophrenia and as both monotherapy and combination therapy for pediatric bipolar disorder. Studies to date indicate that risperidone is an effective treatment for positive and negative symptoms of schizophrenia and mania symptoms of bipolar disorder. In young patient populations, side effects such as weight gain, extrapyramidal side effects, and prolactin elevation require consideration when evaluating the risk benefit ratio for individual patients. Here we review published studies of risperidone for the treatment of bipolar disorder and schizophrenia in children and adolescents to provide practitioners with an overview of published data on the efficacy and safety of risperidone in these patient populations. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 91 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 1% |
| India | 1 | 1% |
| United Kingdom | 1 | 1% |
| Iran, Islamic Republic of | 1 | 1% |
| United States | 1 | 1% |
| Unknown | 86 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 16 | 18% |
| Student > Bachelor | 13 | 14% |
| Student > Master | 11 | 12% |
| Student > Ph. D. Student | 10 | 11% |
| Student > Doctoral Student | 6 | 7% |
| Other | 20 | 22% |
| Unknown | 15 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 29 | 32% |
| Psychology | 14 | 15% |
| Neuroscience | 10 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 5% |
| Nursing and Health Professions | 3 | 3% |
| Other | 11 | 12% |
| Unknown | 19 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 May 2013.
All research outputs
#7,960,512
of 25,374,917 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,035
of 3,132 outputs
Outputs of similar age
#32,189
of 95,559 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#17
of 29 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 3,132 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 95,559 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.